Eric Lefkofsky, Executive Director and President Tempus ai Inch. (Nasdaq :), recently sold a significant part of his possession, with a total value of approximately $ 62 million. Transactions published in Form 4 submitted Commission for Securities and Stock Exchange have happened for several days. Sales are made in the middle of a significant increase in TEM shares of 46% over last week. According to InvestingproThe company, currently estimated at $ 8.63 billion, has shown a strong momentum despite the loss business.
Lefkofsky sold a number of shares on January 22 at prices of $ 47.78 to $ 51.82. These sales included 30 609 shares of $ 47.78 each, 101 967 shares each each of a $ 49.06 and 238 699 stocks each of each 49.84 USD. Additional transactions included 60,587 shares of $ 50.70 and $ 41,747 each of a $ 51.82.
The following day, January 2, January, there was a further sale with 24 677 shares sold each each each of the USD and 61 987 shares each each of each $ 48.57. Specifically, a higher transaction included 365,467 shares at a price of $ 52.79.
On January 24, Lefkofsky continued the trend, selling 71,333 shares of $ 53.26 each and $ 11,355 each at $ 53.84. The last transaction on that day included 3100 shares sold each with $ 54.75.
These transactions were part of an authorized “sales for coverage” to fulfill the tax liabilities related to the acquisition of limited shareholders, as stated in the submission. After these sales, Lefkofsky retains ownership of several million shares, directly and indirectly through various entities. Investingpro Subscribers can access additional insights, including 8 more professional tips and detailed financial metrics for theme.
In other recent news, Tempus AI, AI company AI company, has reported an impressive increase in revenue of 30% for 2024, with a total revenue of approximately $ 693 million. In the fourth quarter alone, revenues of around $ 200 million were recorded, representing a growth of 35% compared to the previous year. The company also launched the Olivia application for personal health, aimed at centralizing data on patients’ health and providing insights on artificial intelligence. Furthermore, Tempus AI announced the development of the sequencing test of the entire genome, called XH, which is currently available for research purposes and is expected to be clinically available over the next year. As for the update of analysts, Loop Capital reduced the target price for Tempus AI from $ 57.00 to $ 52.00, retaining the Kupi rating. Similarly, Piper Sandler has raised the targeted price for Tempus AI from $ 40 to $ 70, retaining a neutral rating. Stifel, however, reduced the rating of the Tempus AI shares with Buy to Hold, but increased the target price to $ 65. These are recent achievements for tempus AI.
This article was generated with the support of artificial intelligence and was examined by the editor. See our T&C for more information.
